Schweppes Zero Sugar Ginger Ale Caffeine Free recalled as it contains Sugar
1 week ago •source accessdata.fda.gov
Recall notice
Pepsico Inc has voluntarily recalled its Schweppes Zero Sugar Ginger Ale Caffeine Free product due to a labeling error. The product, which was distributed in Maryland, Pennsylvania, and West Virginia, was found to contain full sugar despite being labeled as zero sugar. The labeling error was discovered
during an internal investigation by the firm. The recall is ongoing and was initiated on March 9, 2024.
The recalled product is the Schweppes Zero Sugar Ginger Ale Caffeine Free, 7.5 FL OZ (221 mL), produced under the authority of Dr. Pepper/Seven Up, Inc. The product carries the UPC 0 78000 02965 9 and is sold in 24 pack cases, with a total of 233 cases being recalled. The affected batches have the code information May 20 24 MAY20240520VS02164 - MAY20240550VS02164.
If you have this product at home and are concerned about sugar intake, do not consume it and return it to the store where it was purchased.
If you or a loved one are harmed or experiencing any symptoms, it is important to report it. Reporting can help to detect & resolve outbreaks early and prevent others from being harmed, and enables better surveillance. If symptoms persist, seek medical care.
Source: www.accessdata.fda.gov
The recalled product is the Schweppes Zero Sugar Ginger Ale Caffeine Free, 7.5 FL OZ (221 mL), produced under the authority of Dr. Pepper/Seven Up, Inc. The product carries the UPC 0 78000 02965 9 and is sold in 24 pack cases, with a total of 233 cases being recalled. The affected batches have the code information May 20 24 MAY20240520VS02164 - MAY20240550VS02164.
If you have this product at home and are concerned about sugar intake, do not consume it and return it to the store where it was purchased.
If you or a loved one are harmed or experiencing any symptoms, it is important to report it. Reporting can help to detect & resolve outbreaks early and prevent others from being harmed, and enables better surveillance. If symptoms persist, seek medical care.
Source: www.accessdata.fda.gov
82
